HER2-Low Breast Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of HER2-Low Breast Cancer

Featuring perspectives from Dr Aditya Bardia, Dr Lisa A Carey, Dr Shanu Modi and Prof Peter Schmid, including the following topics:    • Introduction (0:00) • Optimal Approaches to HER2 Testing for the Identification of HER2-Low Breast Cancer — Dr Carey (3:27) • Available Data with and Current Role of HER2-Targeted Therapy for HER2-Low Disease — Dr Modi (22:41) • Identification and Management of Toxicities with Trastuzumab Deruxtecan — Prof Schmid (48:20) • Future Directions in the Management of HER2-Low Breast Cancer — Dr Bardia (1:10:18) CME information and select publications